Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Peyrin-Biroulet L, Ghosh S, Lee SD, Lee WJ, Griffith J, Wallace K, Berg S, Liao X, Panes J, Loftus EV Jr, Louis E. Peyrin-Biroulet L, et al. Among authors: griffith j. Aliment Pharmacol Ther. 2023 Mar;57(5):496-508. doi: 10.1111/apt.17242. Epub 2022 Oct 20. Aliment Pharmacol Ther. 2023. PMID: 36266762 Free article.
Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.
Loftus EV Jr, Griffith J, Neimark E, Song A, Wallace K, Nannapaneni S, Zhou J, Byrne R, Kligys K, Pang Y, Liao X, Kalabic J, Dubinsky M. Loftus EV Jr, et al. Among authors: griffith j. Adv Ther. 2023 May;40(5):2311-2325. doi: 10.1007/s12325-023-02477-2. Epub 2023 Mar 14. Adv Ther. 2023. PMID: 36917429 Free PMC article. Clinical Trial.
Economic Burden of Fatigue in Inflammatory Bowel Disease.
Ananthakrishnan AN, Desai R, Lee WJ, Griffith J, Chen N, Loftus EV Jr. Ananthakrishnan AN, et al. Among authors: griffith j. Crohns Colitis 360. 2023 Apr 20;5(3):otad020. doi: 10.1093/crocol/otad020. eCollection 2023 Jul. Crohns Colitis 360. 2023. PMID: 37663925 Free PMC article.
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Colombel JF, Schreiber S, D'Haens G, Rizzo J, Kligys K, Griffith J, Zambrano J, Zhou Q, Zhang Y, Kalabic J, Rieder F, Dubinsky MC, Panaccione R. Colombel JF, et al. Among authors: griffith j. J Crohns Colitis. 2024 Jun 3;18(6):818-827. doi: 10.1093/ecco-jcc/jjad206. J Crohns Colitis. 2024. PMID: 38069472 Free PMC article. Clinical Trial.
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials.
Panaccione R, Ma C, Jairath V, Dignass A, Joshi N, Clark R, Griffith J, Kligys K, Semwal M, Smith Z, Mitchell D, Nunag D, Ferrante M. Panaccione R, et al. Among authors: griffith j. J Crohns Colitis. 2024 Aug 30:jjae128. doi: 10.1093/ecco-jcc/jjae128. Online ahead of print. J Crohns Colitis. 2024. PMID: 39212931
Mucosal and Transmural Healing and Long-term Outcomes in Crohn's Disease.
Sands BE, Danese S, Chapman JC, Gurjar K, Grieve S, Thakur D, Griffith J, Joshi N, Kligys K, Dignass A. Sands BE, et al. Among authors: griffith j. Inflamm Bowel Dis. 2024 Jul 31:izae159. doi: 10.1093/ibd/izae159. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 39083264
2,326 results